Table 2 Unadjusted treatment patterns
All Patients | Pirfenidone | Nintedanib | P Value1 | |
|---|---|---|---|---|
N = 1455 | N = 799 | N = 656 | ||
Follow-Up | ||||
Days of follow-up after index date, mean (SD) | 465.0 (343.9) | 480.2 (351.4) | 446.6 (334.0) | 0.064 |
Adherence | ||||
Total days with index drug, mean (SD)2 | 269.0 (277.8) | 282.7 (289.7) | 252.4 (261.8) | 0.038 |
PDC during follow-up, mean (SD) | 0.66 (0.35) | 0.66 (0.35) | 0.66 (0.35) | 0.910 |
PDC ≥ 0.80, n (%) | 721 (49.6) | 390 (48.8) | 331 (50.5) | 0.532 |
Persistence | ||||
Duration of persistence in days, mean (SD)3 | 286.8 (301.4) | 305.2 (314.7) | 264.4 (282.9) | 0.010 |
Discontinuation or switching, n (%)3 | 610 (41.9) | 326 (40.8) | 284 (43.3) | 0.338 |
Days on index medication in patients who discontinued or switched, mean (SD) | 167.4 (189.8) | 171.2 (190.5) | 163.1 (189.4) | 0.598 |
Switching, n (%) | 144 (9.9) | 86 (10.8) | 58 (8.8) | 0.222 |
Days on index medication in patients who switched, mean (SD) | 297.9 (210.1) | 251.4 (184.7) | 366.9 (227.5) | 0.001 |
Other discontinuation-related outcomes | ||||
Lung transplant, n (%) | 82 (5.6) | 53 (6.6) | 29 (4.4) | 0.069 |
Discontinuation before lung transplant, n (%)3,4 | 36 (43.9) | 21 (39.6) | 15 (51.7) | 0.291 |
Re-initiation of index medication, n (%)5 | 101 (16.1) | 61 (17.8) | 40 (14.0) | 0.197 |
Days to re-initiation, mean (SD)6 | 157.3 (122.0) | 150.4 (107.4) | 167.9 (142.2) | 0.484 |